• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » September 2010 – The CenterWatch Monthly : PDF
September 2010 – The CenterWatch Monthly : PDF

September 2010 – The CenterWatch Monthly : PDF

$79.00

Product Details

"Sunshine law" puts cloud of concern over sponsors, sites

The sunshine law, part of the recent healthcare reform legislation, creates significant new obligations for drug sponsors by requiring that annual reports be submitted detailing their financial relationships with physicians and teaching hospitals. Both sponsors and investigative sites are trying to understand the scope of the law and have questioned whether it's possible to prevent a variety of unintended consequences that could harm clinical research and competitive confidentiality.

Academic Medical Centers and industry: Friends or foes?

Since drug development began, dysfunction and trouble have plagued the relationship between the commercial side of the industry -- sponsors and CROs -- and the academic side -- AMCs. Industry has long bemoaned that AMCs are too big, too slow, and too bureaucratic, while AMCs have complained that industry doesn't care about the patient or the science, but just wants to make money. Through the years, this tempestuous relationship has led the pendulum to swing both toward and away from collaboration, leading observers of the drug development process to question whether the two should work together at all. But as the industry matures and economic conditions remain tight, both sides are now striving to create better, more strategic partnerships.

Eye On: AstraZeneca

CenterWatch launches its new Eye On focusing on a single company's drug development pipeline this month with AstraZeneca, a worldwide biopharmaceutical company involved in discovery, development, manufacturing and marketing prescription drugs for six major therapeutic areas. Its strongest focus in terms of numbers of drugs in its pipeline includes oncology/inflammation, neuroscience and respiratory/inflammation. Other therapeutic areas include cardiovascular, gastrointestinal and infection. Research and development expenditures in 2008 exceeded $5 billion.

  • Month in Review
  • In the Pipeline
  • TrialWatch
  • Opportunities Initiating
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing